Donepezil
Aricept — a reversible acetylcholinesterase inhibitor
Donepezil (Aricept — a reversible acetylcholinesterase inhibitor) is a cognitive & mood research compound. Reversible inhibition of acetylcholinesterase, raising acetylcholine concentration by slowing its hydrolysis rather than by adding transmitter. The effect therefore scales with how much acetylcholine a neuron is still releasing, which is the quantity a degenerating cholinergic system is losing — so the pharmacology has a built-in ceiling in the disease it treats. Metabolized by CYP2D6 and CYP3A4, and 96% bound to plasma protein.
Donepezil quick facts
| Route | Oral |
| Frequency | Per prescription · Per prescription |
| Half-life | ~70 hrs — about two weeks to steady state, so a three-day trial measures half the eventual exposure |
| Forms | Oral |
| Evidence level | Approved for mild, moderate and severe Alzheimer's dementia. Its own label states there is no evidence it alters the course of the underlying disease. |
The most important sentence about this drug is in its own FDA label: there is no evidence donepezil alters the course of the underlying dementing process. It treats a symptom. In the largest pooled dataset it improved MMSE by 1.41 points against a clinical-importance threshold of 1.40 — a real, replicated, very small effect. In the largest network meta-analysis, aerobic exercise and cognitive training both scored higher than it did. And the Cochrane review found that stopping a cholinesterase inhibitor cost 2.09 MMSE points at twelve months, which is a larger number than the treatment gain. Prescription medicine, no buy button.
How Donepezil works
Reversible inhibition of acetylcholinesterase, raising acetylcholine concentration by slowing its hydrolysis rather than by adding transmitter. The effect therefore scales with how much acetylcholine a neuron is still releasing, which is the quantity a degenerating cholinergic system is losing — so the pharmacology has a built-in ceiling in the disease it treats. Metabolized by CYP2D6 and CYP3A4, and 96% bound to plasma protein.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Donepezil
Buy Donepezil at RUPharma →Approved for Alzheimer's dementia, and its own label states there is no evidence it alters the course of the underlying disease.
It carries bradycardia, heart-block and syncope warnings, and the people who get caught are the ones with conduction disease nobody has told them about. A resting pulse and an ECG are worth more here than any single blood marker; on the bloodwork side, electrolytes and thyroid are what make a slow heart slower.
Order these through my Marek link →The evidence for Donepezil
Graded by what exists behind each claim.
✅ Clinically validated
- Its own FDA label states there is no evidence donepezil alters the course of the underlying dementing process. It treats a symptom. Approved for mild, moderate and severe Alzheimer's dementia.
- In the 80-trial, 21,138-participant individual-patient network meta-analysis it improved MMSE by 1.41 points (95% CI 0.51-2.32) against the reviewers' own 1.40-point threshold for clinical importance, and the donepezil-plus-memantine combination by 2.57 (Veroniki 2022).
- The Cochrane review found that stopping a cholinesterase inhibitor was associated with cognition worse by 2.09 SMMSE points and function worse by 3.38 BADLS points at twelve months (Parsons 2021) — a larger number than the pooled treatment gain.
📊 Correlative data
- The 2026 network meta-analysis of 125 trials in over 30,000 people scored it at 0.21, with aerobic exercise at 0.55 and cognitive training at 0.45 in the same network (Li 2026).
- No trial in cognitively normal adults exists, so every nootropic claim for this molecule is extrapolation across a population boundary rather than evidence.
🧪 Theoretical / extrapolated
- Reversible acetylcholinesterase inhibition raises acetylcholine by slowing its breakdown rather than adding transmitter, so the effect scales with how much a neuron is still releasing — a built-in ceiling in the disease it treats and, arguably, in a healthy brain too.
- Predicted downside, from the label: bradycardia, heart block and syncope from cholinergic slowing of the sinus node; and at the 23 mg strength, peptic ulcer disease rising from 0.2% to 0.4% with gastrointestinal bleeding and weight loss in 4.7%.
- A ~70 hour half-life and 96% protein binding mean two weeks to steady state, and CYP2D6 variability means two people on identical tablets can sit at materially different exposures.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Donepezil actually does
The label contains the one sentence a nootropics buyer most needs and least expects. Aricept's prescribing information states: “There is no evidence that donepezil alters the course of the underlying dementing process” Aricept label 2021. That is the manufacturer, in the approved label, saying the drug treats a symptom and does not touch the disease. Everything else on this page is downstream of it.
The mechanism, stated exactly. Donepezil is postulated to act by reversible inhibition of acetylcholinesterase, raising the concentration of acetylcholine by slowing its hydrolysis Aricept label 2021. It adds no transmitter. It slows the removal of what a neuron already released, which means the effect scales with how much acetylcholine there still is to preserve — and that is the quantity a degenerating cholinergic system is losing. A pharmacology built on preserving output has an obvious ceiling in a system that has stopped producing.
What it is approved for, and how wide that is. Unusually for this class, the indication covers mild, moderate and severe dementia of the Alzheimer's type Aricept label 2021 — broader than memantine's moderate-to-severe indication. It is still a dementia indication. It is a prescription medicine, sold by a partner at $80 for 10 mg tablets, and this page carries no purchase route.
Why the same class contains a drug with an excess-death signal. Galantamine, its class-mate, carries a mild cognitive impairment mortality paragraph in its own label. Donepezil does not. The two facts sit together because a class argument is not a molecule argument, and reading across from one cholinesterase inhibitor to another is the move both labels quietly refuse to make.
Cell, rodent, human — and where it stops
It is the best-performing single agent in the largest pooled dataset, and the size of that win is the point. Veroniki 2022 pooled 80 randomized trials and 21,138 adults. Donepezil improved Mini-Mental State Examination score by 1.41 points (95% CI 0.51 to 2.32) against placebo, and donepezil plus memantine by 2.57 (0.07 to 5.07). The reviewers' own threshold for clinical importance was 1.40 MMSE points. Donepezil cleared it by 0.01. That is a real effect, replicated, on a 30-point scale, and it is sitting on the line the authors drew.
The newer network puts a number on it and a behavior above it. Li 2026 synthesized 125 phase II and III trials in over 30,000 people. Donepezil returned a standardized mean difference of 0.21 (95% credible interval 0.11 to 0.30). In the same analysis aerobic exercise scored 0.55, cognitive training 0.45 and galantamine 0.40. The authors are explicit that the non-drug arms are short-term and adjunctive. Even read conservatively, the drug that anchors dementia prescribing is not the top-ranked intervention in the field's largest network.
The population, and it is not the reader. Every participant in both syntheses had diagnosed Alzheimer's dementia, and the 2025 guideline recommends the class for that diagnosis Kim 2025. There is no equivalent body of work in healthy adults, which means the entire nootropic use of this molecule runs on a mechanism argument — more acetylcholine is better — that the trials never tested in anyone with a normal cholinergic system.
And the exit is better studied than the entrance, with an awkward result. Parsons 2021 pooled six trials, 759 participants. At twelve months, discontinuing a cholinesterase inhibitor was associated with cognition worse by 2.09 points on the Standardized Mini-Mental State Examination (95% CI -3.43 to -0.75, moderate certainty) and function worse by 3.38 points on the Bristol Activities of Daily Living Scale. Read carefully: the withdrawal penalty at twelve months is larger than the pooled treatment gain. A drug whose stopping effect exceeds its starting effect is not one to try casually.
Donepezil pharmacokinetics — how much of it actually gets in
Seventy hours, and almost nobody dosing this drug behaves as though that is true. Elimination half-life is approximately 70 hours Aricept label 2021. Five half-lives is about two weeks to steady state, so the concentration on day 3 is roughly half what it will be on day 14 at the same dose. Every anecdote written after a few days is an anecdote about the wrong concentration, and the label's stepped titration exists because of this number.
Ninety-six percent bound, and two enzymes doing the clearing. Plasma protein binding is approximately 96%, and metabolism runs through CYP2D6 and CYP3A4 Aricept label 2021. CYP2D6 is the interesting one: it is genetically variable, a meaningful share of people carry reduced-function or non-functional copies, and the same enzyme is inhibited by several common antidepressants. Two people on identical tablets can therefore sit at materially different exposures, and neither can tell from the outside.
The one absorption fact, and it is permissive. The label states the rate and extent of absorption are not influenced by food Aricept label 2021. Peak concentration is reached at about 3 hours for the 10 mg tablet and about 8 hours for the 23 mg tablet — the higher strength is a different absorption profile, not simply more of the same one.
What the 23 mg strength bought, in the label's own numbers. Against 10 mg it came with higher discontinuation, weight loss reported as an adverse reaction in 4.7%, and an increase in peptic ulcer disease from 0.2% to 0.4% with gastrointestinal bleeding Aricept label 2021. That is what a dose-response curve looks like when the toxicity outruns the benefit, and it is the argument against the reflex that if a little acetylcholinesterase inhibition helps, more will help more.
What would have to be true, and how you would know it was not
Three predictions, and the second is the cheapest and least flattering.
1. MMSE or MoCA at baseline and 12 weeks. In diagnosed dementia the pooled gain is 1.41 MMSE points Veroniki 2022. In a cognitively normal adult, prediction: no change beyond test-retest variation. The mechanism supports this rather than contradicting it — a drug that works by slowing the breakdown of released acetylcholine has least to add in a system releasing a normal amount.
2. Resting heart rate, measured for a week before and a week after starting. Enhanced cholinergic tone slows the sinus node, and the label carries warnings for bradycardia and heart block with syncope Aricept label 2021. Prediction: resting heart rate falls by a few beats per minute. Anyone wearing a tracker already has this measurement, it requires no clinic, and a fall large enough to notice is a reason to talk to a prescriber rather than a sign the drug is working.
3. Against the drug: body weight at 12 weeks. The label reports weight loss as an adverse reaction in 4.7% at the higher strength Aricept label 2021, and cholinergic gastrointestinal effects are the class's most common complaint. For a reader whose goals include training, that is a cost on the same ledger as the hoped-for benefit, and it is measured with a bathroom scale.
What nobody has tested yet
Nobody has run an adequately powered trial in healthy adults. The two large syntheses above cover 21,138 and 30,000-plus participants and all of them had a diagnosis Veroniki 2022 Li 2026. The nootropic claim for this molecule is therefore not weakly supported; it is unsupported in the specific sense that the study has not been done. That is a solvable problem and has been solvable for twenty-five years.
Nobody has published a CYP2D6-stratified exposure study in self-medicating users. The enzyme is genetically variable, the label names it Aricept label 2021, and consumer genotyping is now cheap. What does not exist is any dataset connecting genotype, plasma concentration and either benefit or cholinergic side effects in people taking this outside a clinic.
Nobody has tested the drug against the top-ranked non-drug arm. Li 2026 ranks aerobic exercise at 0.55 and this drug at 0.21 in the same network, which is an indirect comparison assembled from separate trials. A head-to-head randomized study with one cognitive endpoint would settle it. It has not been run, and the ranking will stay arguable until it is.
Extrapolation, labeled as such. If the mechanism is preservation of released acetylcholine, three things follow that nobody has looked for: benefit should be largest where cholinergic loss is greatest and therefore should correlate with basal forebrain volume on imaging that many participants already have; it should be absent in healthy volunteers; and it should be reduced by anticholinergic medicines taken concurrently, which is an interaction the label warns about qualitatively and nobody has quantified.
Donepezil — its own safety story, not its class's
Three things specific to this drug rather than to its class.
The heart is the organ to think about first. Cholinergic enhancement slows conduction, and the label warns about bradycardia and heart block with syncopal episodes Aricept label 2021. The people at risk are those with existing conduction disease, and a large share of them do not know they have it. This is not a theoretical mechanism; it is the reason an electrocardiogram before starting is ordinary practice and the reason this page has no buy button.
The gut is the organ to think about second, and the higher dose makes it worse. The label reports peptic ulcer disease rising from 0.2% to 0.4% and gastrointestinal bleeding at the 23 mg strength Aricept label 2021. That risk is multiplied by anything else raising it — regular non-steroidal anti-inflammatories, which is an extremely common habit in a training population, and alcohol.
And the exit has a measured cost. Stopping a cholinesterase inhibitor after long use was associated with cognition worse by 2.09 SMMSE points and function worse by 3.38 BADLS points at twelve months Parsons 2021. Those data come from people with dementia and do not transfer automatically to anyone else. What they do establish is that this class is not a substance you sample and put down without consequence in the population where it has actually been studied, and no data exist for the population reading this.
Sources read for this page
- U.S. Food and Drug Administration. ARICEPT (donepezil hydrochloride) tablets and orally disintegrating tablets - full prescribing information, including the mechanism-of-action statement, the pharmacokinetics section, and the bradycardia, gastrointestinal bleeding and 23 mg tolerability sections. DailyMed, U.S. National Library of Medicine; Eisai Inc. label revised December 2021
- Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ Open 2022 · PMID 35473731
- Li Y, Li L, Yang Q, Xiong J. Comparative Efficacy and Safety of Cholinesterase Inhibitors and NMDA Receptor Antagonists in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. Current Alzheimer Research 2026 · PMID 42099163
- Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database of Systematic Reviews 2021 · PMID 35608903
- Kim Y, Kang DW, Kim GH, et al. (Korean Dementia Association). Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine. Dementia and Neurocognitive Disorders 2025 · PMID 39944527
Donepezil — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Donepezil moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Donepezil in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Donepezil
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Donepezil — frequently asked questions
What is Donepezil?
Donepezil (Aricept — a reversible acetylcholinesterase inhibitor) is a cognitive & mood research compound. Reversible inhibition of acetylcholinesterase, raising acetylcholine concentration by slowing its hydrolysis rather than by adding transmitter. The effect therefore scales with how much acetylcholine a neuron is still releasing, which is the quantity a degenerating cholinergic system is losing — so the pharmacology has a built-in ceiling in the disease it treats. Metabolized by CYP2D6 and CYP3A4, and 96% bound to plasma protein.
Where can I find Donepezil dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Donepezil protocol are available to members inside Skool. This public page covers what Donepezil is, how it works and the evidence.
What is the half-life of Donepezil?
Donepezil has an approximate half-life of ~70 hrs — about two weeks to steady state, so a three-day trial measures half the eventual exposure, which is part of what determines how often it's dosed.
What's the evidence behind Donepezil?
Current evidence level: Approved for mild, moderate and severe Alzheimer's dementia. Its own label states there is no evidence it alters the course of the underlying disease.. Donepezil is offered for research purposes only and is not an approved medicine.
What Donepezil is used for
Donepezil appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.